Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Supplementary physicians' fees: a sustainable system?

Calcoen P, van de Ven WPMM.

Health Econ Policy Law. 2019 Jan;14(1):40-60. doi: 10.1017/S1744133117000548. Epub 2018 Jan 25.

PMID:
29366440
2.

How can dental insurance be optimized?

Calcoen P, van de Ven WPMM.

Eur J Health Econ. 2018 May;19(4):483-487. doi: 10.1007/s10198-017-0938-y. No abstract available.

3.

Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.

Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, Huisman HJ.

World J Urol. 2017 Dec;35(12):1849-1855. doi: 10.1007/s00345-017-2085-6. Epub 2017 Sep 4.

4.

Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.

Willemse-Duijmelinck DMID, van de Ven WPMM, Mosca I.

Health Policy. 2017 Oct;121(10):1085-1092. doi: 10.1016/j.healthpol.2017.08.003. Epub 2017 Aug 10.

PMID:
28855064
5.

Can premium differentiation counteract adverse selection in the Dutch supplementary health insurance? A simulation study.

van Winssen KPM, van Kleef RC, van de Ven WPMM.

Eur J Health Econ. 2018 Jun;19(5):757-768. doi: 10.1007/s10198-017-0918-2. Epub 2017 Jul 31.

6.

Should new health technology be available only for patients able and willing to pay?

Calcoen P, Boer A, van de Ven WPMM.

J Mark Access Health Policy. 2017 May 4;5(1):1315294. doi: 10.1080/20016689.2017.1315294. eCollection 2017. Review.

7.

PLAG1 deficiency impairs spermatogenesis and sperm motility in mice.

Juma AR, Grommen SVH, O'Bryan MK, O'Connor AE, Merriner DJ, Hall NE, Doyle SR, Damdimopoulou PE, Barriga D, Hart AH, Van de Ven WJM, De Groef B.

Sci Rep. 2017 Jul 13;7(1):5317. doi: 10.1038/s41598-017-05676-4.

8.

Exploring the predictive power of interaction terms in a sophisticated risk equalization model using regression trees.

van Veen SHCM, van Kleef RC, van de Ven WPMM, van Vliet RCJA.

Health Econ. 2018 Feb;27(2):e1-e12. doi: 10.1002/hec.3523. Epub 2017 May 23.

PMID:
28544104
9.

Different Endomembrane Trafficking Pathways Establish Apical and Basal Polarities.

Li R, Rodriguez-Furlan C, Wang J, van de Ven W, Gao T, Raikhel NV, Hicks GR.

Plant Cell. 2017 Jan;29(1):90-108. doi: 10.1105/tpc.16.00524. Epub 2016 Dec 23. Erratum in: Plant Cell. 2018 Aug;30(8):1943-1945.

10.

Improving risk equalization with constrained regression.

van Kleef RC, McGuire TG, van Vliet RCJA, van de Ven WPPM.

Eur J Health Econ. 2017 Dec;18(9):1137-1156. doi: 10.1007/s10198-016-0859-1. Epub 2016 Dec 10.

11.

Potential determinants of deductible uptake in health insurance: How to increase uptake in The Netherlands?

van Winssen KP, van Kleef RC, van de Ven WP.

Eur J Health Econ. 2016 Dec;17(9):1059-1072. Epub 2015 Nov 27.

12.

Synthesis and Characterization of Curcumin-Functionalized HP-β-CD-Modified GoldMag Nanoparticles as Drug Delivery Agents.

Lian T, Peng M, Vermorken AJ, Jin Y, Luo Z, Van de Ven WJ, Wan Y, Hou P, Cui Y.

J Nanosci Nanotechnol. 2016 Jun;16(6):6258-64.

PMID:
27427699
13.

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.

van de Ven WJ, Sedelaar JP, van der Leest MM, Hulsbergen-van de Kaa CA, Barentsz JO, Fütterer JJ, Huisman HJ.

Clin Imaging. 2016 Jul-Aug;40(4):745-50. doi: 10.1016/j.clinimag.2016.02.005. Epub 2016 Feb 6.

PMID:
27317220
14.

MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience.

van de Ven WJ, Venderink W, Sedelaar JP, Veltman J, Barentsz JO, Fütterer JJ, Cornel EB, Huisman HJ.

Int Urol Nephrol. 2016 Jul;48(7):1037-45. doi: 10.1007/s11255-016-1283-2. Epub 2016 Apr 11.

15.

What can Europe learn from the managed care backlash in the United States?

Duijmelinck D, van de Ven W.

Health Policy. 2016 May;120(5):509-18. doi: 10.1016/j.healthpol.2016.03.010. Epub 2016 Mar 22. Review.

PMID:
27055353
16.

Improving access to essential health care services: the case of Israel.

van de Ven WP.

Isr J Health Policy Res. 2016 Mar 4;5:3. doi: 10.1186/s13584-016-0063-x. eCollection 2016.

17.

The demand for health insurance and behavioural economics.

van Winssen KP, van Kleef RC, van de Ven WP.

Eur J Health Econ. 2016 Jul;17(6):653-7. doi: 10.1007/s10198-016-0776-3. No abstract available.

PMID:
26923250
18.

A voluntary deductible in health insurance: the more years you opt for it, the lower your premium?

van Winssen KP, van Kleef RC, van de Ven WP.

Eur J Health Econ. 2017 Mar;18(2):209-226. doi: 10.1007/s10198-016-0767-4. Epub 2016 Feb 9.

19.

How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.

van de Ven WP, van Vliet RC, van Kleef RC.

Eur J Health Econ. 2017 Mar;18(2):167-180. doi: 10.1007/s10198-016-0764-7. Epub 2016 Feb 2.

20.

Endosidin2 targets conserved exocyst complex subunit EXO70 to inhibit exocytosis.

Zhang C, Brown MQ, van de Ven W, Zhang ZM, Wu B, Young MC, Synek L, Borchardt D, Harrison R, Pan S, Luo N, Huang YM, Ghang YJ, Ung N, Li R, Isley J, Morikis D, Song J, Guo W, Hooley RJ, Chang CE, Yang Z, Zarsky V, Muday GK, Hicks GR, Raikhel NV.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E41-50. doi: 10.1073/pnas.1521248112. Epub 2015 Nov 25.

21.

Emerging role of PLAG1 as a regulator of growth and reproduction.

Juma AR, Damdimopoulou PE, Grommen SV, Van de Ven WJ, De Groef B.

J Endocrinol. 2016 Feb;228(2):R45-56. doi: 10.1530/JOE-15-0449. Epub 2015 Nov 17. Review.

PMID:
26577933
22.

Risk Selection Threatens Quality Of Care For Certain Patients: Lessons From Europe's Health Insurance Exchanges.

van de Ven WP, van Kleef RC, van Vliet RC.

Health Aff (Millwood). 2015 Oct;34(10):1713-20. doi: 10.1377/hlthaff.2014.1456.

PMID:
26438748
23.

Overpaying morbidity adjusters in risk equalization models.

van Kleef RC, van Vliet RC, van de Ven WP.

Eur J Health Econ. 2016 Sep;17(7):885-95. doi: 10.1007/s10198-015-0729-2. Epub 2015 Sep 29.

PMID:
26420555
24.

Switching rates in health insurance markets decrease with age: empirical evidence and policy implications from the Netherlands.

Duijmelinck DM, van de Ven WP.

Health Econ Policy Law. 2016 Apr;11(2):141-59. doi: 10.1017/S1744133115000328. Epub 2015 Jul 15.

PMID:
26173559
25.

Dextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo.

Peng M, Li H, Luo Z, Kong J, Wan Y, Zheng L, Zhang Q, Niu H, Vermorken A, Van de Ven W, Chen C, Zhang X, Li F, Guo L, Cui Y.

Nanoscale. 2015 Jul 7;7(25):11155-62. doi: 10.1039/c5nr01382h.

PMID:
26062012
26.

Biomechanical modeling constrained surface-based image registration for prostate MR guided TRUS biopsy.

van de Ven WJ, Hu Y, Barentsz JO, Karssemeijer N, Barratt D, Huisman HJ.

Med Phys. 2015 May;42(5):2470-81. doi: 10.1118/1.4917481.

PMID:
25979040
27.

How profitable is a voluntary deductible in health insurance for the consumer?

van Winssen KP, van Kleef RC, van de Ven WP.

Health Policy. 2015 May;119(5):688-95. doi: 10.1016/j.healthpol.2015.02.009. Epub 2015 Feb 21.

PMID:
25747511
28.

Is there one measure-of-fit that fits all? A taxonomy and review of measures-of-fit for risk-equalization models.

van Veen SH, van Kleef RC, van de Ven WP, van Vliet RC.

Med Care Res Rev. 2015 Apr;72(2):220-43. doi: 10.1177/1077558715572900. Epub 2015 Feb 18. Review.

PMID:
25694164
29.

Switching benefits and costs in competitive health insurance markets: A conceptual framework and empirical evidence from the Netherlands.

Duijmelinck DM, Mosca I, van de Ven WP.

Health Policy. 2015 May;119(5):664-71. doi: 10.1016/j.healthpol.2014.11.015. Epub 2014 Nov 29.

PMID:
25530069
31.

Improved estimates of Belgian private health expenditure can give important lessons to other OECD countries.

Calcoen P, Moens D, Verlinden P, van de Ven WP, Pacolet J.

Health Policy. 2015 Mar;119(3):341-55. doi: 10.1016/j.healthpol.2014.07.008. Epub 2014 Jul 18.

PMID:
25108312
32.

Improving the prediction model used in risk equalization: cost and diagnostic information from multiple prior years.

van Veen SH, van Kleef RC, van de Ven WP, van Vliet RC.

Eur J Health Econ. 2015 Mar;16(2):201-18. doi: 10.1007/s10198-014-0567-7. Epub 2014 Feb 12.

PMID:
24519402
33.

Evaluation of prostate segmentation algorithms for MRI: the PROMISE12 challenge.

Litjens G, Toth R, van de Ven W, Hoeks C, Kerkstra S, van Ginneken B, Vincent G, Guillard G, Birbeck N, Zhang J, Strand R, Malmberg F, Ou Y, Davatzikos C, Kirschner M, Jung F, Yuan J, Qiu W, Gao Q, Edwards PE, Maan B, van der Heijden F, Ghose S, Mitra J, Dowling J, Barratt D, Huisman H, Madabhushi A.

Med Image Anal. 2014 Feb;18(2):359-73. doi: 10.1016/j.media.2013.12.002. Epub 2013 Dec 25.

34.

Risk selection in a regulated health insurance market: a review of the concept, possibilities and effects.

van Kleef RC, van de Ven WP, van Vliet RC.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):743-52. doi: 10.1586/14737167.2013.841546. Review.

PMID:
24219050
35.

Risk equalization in The Netherlands: an empirical evaluation.

Van Kleef RC, Van Vliet RC, Van de Ven WP.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):829-39. doi: 10.1586/14737167.2013.842127. Epub 2013 Nov 1.

PMID:
24175733
36.

Prostate cancer: MRI/US-guided biopsy--a viable alternative to TRUS-guidance.

van de Ven WJ, Barentsz JO.

Nat Rev Urol. 2013 Oct;10(10):559-60. doi: 10.1038/nrurol.2013.179. Epub 2013 Aug 13. No abstract available.

PMID:
23938941
37.

Choice of insurer for basic health insurance restricted by supplementary insurance.

Duijmelinck DM, van de Ven WP.

Eur J Health Econ. 2014 Sep;15(7):737-46. doi: 10.1007/s10198-013-0519-7. Epub 2013 Jul 26.

PMID:
23887827
38.

Polyphenols with indirect proprotein convertase inhibitory activity.

Zhu J, Van de Ven W, Vermorken A.

Int J Oncol. 2013 Sep;43(3):947-55. doi: 10.3892/ijo.2013.2009. Epub 2013 Jul 8.

PMID:
23835774
39.

Curcumin affects proprotein convertase activity: elucidation of the molecular and subcellular mechanism.

Zhu J, Bultynck G, Luyten T, Parys JB, Creemers JW, Van de Ven WJ, Vermorken AJ.

Biochim Biophys Acta. 2013 Aug;1833(8):1924-35. doi: 10.1016/j.bbamcr.2013.04.002. Epub 2013 Apr 10.

40.

Preconditions for efficiency and affordability in competitive healthcare markets: are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland?

van de Ven WP, Beck K, Buchner F, Schokkaert E, Schut FT, Shmueli A, Wasem J.

Health Policy. 2013 Mar;109(3):226-45. doi: 10.1016/j.healthpol.2013.01.002. Epub 2013 Feb 8. Review.

PMID:
23399042
41.

Statutory health insurance competition in Europe: a four-country comparison.

Thomson S, Busse R, Crivelli L, van de Ven W, Van de Voorde C.

Health Policy. 2013 Mar;109(3):209-25. doi: 10.1016/j.healthpol.2013.01.005. Epub 2013 Feb 7. Review.

PMID:
23395277
42.

A pattern recognition approach to zonal segmentation of the prostate on MRI.

Litjens G, Debats O, van de Ven W, Karssemeijer N, Huisman H.

Med Image Comput Comput Assist Interv. 2012;15(Pt 2):413-20.

PMID:
23286075
43.

Consumer choice among Mutual Healthcare Purchasers: a feasible option for China?

Xu W, van de Ven WP.

Soc Sci Med. 2013 Nov;96:277-84. doi: 10.1016/j.socscimed.2012.11.029. Epub 2012 Dec 5.

44.

Polyphenols can inhibit furin in vitro as a result of the reactivity of their auto-oxidation products to proteins.

Zhu J, Van de Ven WJ, Verbiest T, Koeckelberghs G, Chen C, Cui Y, Vermorken AJ.

Curr Med Chem. 2013 Feb 1;20(6):840-50.

PMID:
23231348
45.

The level of consumer information about health insurance in Nanjing, China.

Xu W, Van de Ven WP.

Int J Health Plann Manage. 2014 Apr-Jun;29(2):175-96. doi: 10.1002/hpm.2138. Epub 2012 Nov 21.

PMID:
23169306
46.

Arabidopsis ribosomal proteins control developmental programs through translational regulation of auxin response factors.

Rosado A, Li R, van de Ven W, Hsu E, Raikhel NV.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19537-44. doi: 10.1073/pnas.1214774109. Epub 2012 Nov 9.

47.

Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies.

van de Ven WJ, Hulsbergen-van de Kaa CA, Hambrock T, Barentsz JO, Huisman HJ.

Eur Radiol. 2013 May;23(5):1401-7. doi: 10.1007/s00330-012-2701-1. Epub 2012 Nov 9.

PMID:
23138386
48.

A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy.

Chao X, Zhang Z, Guo L, Zhu J, Peng M, Vermorken AJ, Van de Ven WJ, Chen C, Cui Y.

PLoS One. 2012;7(10):e40388. doi: 10.1371/journal.pone.0040388. Epub 2012 Oct 8.

49.

Generation and characterization of non-competitive furin-inhibiting nanobodies.

Zhu J, Declercq J, Roucourt B, Ghassabeh GH, Meulemans S, Kinne J, David G, Vermorken AJ, Van de Ven WJ, Lindberg I, Muyldermans S, Creemers JW.

Biochem J. 2012 Nov 15;448(1):73-82. doi: 10.1042/BJ20120537.

50.

Comment on: Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled crossover 4g study and an open-label 8g extension study.

Vermorken AJ, Zhu J, Van de Ven WJ, Andrès E.

Am J Hematol. 2012 Oct;87(10):E80. doi: 10.1002/ajh.23276. Epub 2012 Jun 20. No abstract available.

Supplemental Content

Loading ...
Support Center